Related Experiment Video

Updated: May 1, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K

Prognostic impact of major receptor tyrosine kinase expression in gastric cancer

Yukinori Kurokawa1, Nariaki Matsuura, Ryohei Kawabata

  • 1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan, ykurokawa@gesurg.med.osaka-u.ac.jp.

Annals of Surgical Oncology
|April 19, 2014
PubMed
Abstract

Insights

Gastric cancer patients with c-Kit receptor tyrosine kinase (RTK) expression showed a significantly better prognosis. This multicenter study evaluated four RTKs, finding c-Kit positivity as a key indicator of good survival outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Receptor tyrosine kinases (RTKs) are key targets for molecularly targeted drugs.
  • The prognostic significance of major RTK expression in gastric cancer is not well understood.
  • This study investigates the prognostic impact of EGFR, c-Met, PDGFR, and c-Kit expression in gastric cancer.

Purpose of the Study:

  • To evaluate the prognostic impact of epidermal growth factor receptor (EGFR), c-Met, platelet-derived growth factor receptor (PDGFR), and c-Kit expression in gastric cancer.
  • To determine if RTK expression status correlates with patient survival outcomes.

Main Methods:

  • A multicenter study involving 153 gastric cancer patients who underwent gastrectomy.
  • Immunohistochemistry (IHC) was used for central evaluation of EGFR, c-Met, PDGFR, and c-Kit expression.
  • Statistical analysis, including Cox multivariate analysis, was performed to assess overall survival based on RTK expression.

Main Results:

  • Positive expression rates were: EGFR (14.4%), c-Met (24.8%), PDGFR (41.2%), and c-Kit (11.1%).
  • Significant interactions were found between RTK expression and clinicopathological factors (e.g., N stage, histology, tumor location).
  • Only c-Kit expression demonstrated a significant association with improved overall survival in Cox multivariate analysis (P=0.046).

Conclusions:

  • Immunohistochemical expression of the four investigated RTKs has a prognostic impact in gastric cancer.
  • c-Kit-positive status may serve as a significant indicator of a favorable prognosis in gastric cancer patients.

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81